AstraZeneca's $2B cancer contender lines up for EU scrutiny

AstraZeneca ($AZN) is expecting word from European regulators next week on whether they'll recommend approval for its new ovarian cancer treatment, a drug the company hopes can bring in $2 billion a year at its peak. The treatment, olaparib, is up for European Medicines Agency review, Reuters reports, and a positive recommendation from the body would spell a likely early approval. AstraZeneca set its $2 billion expectations for the drug during its standoff with Pfizer ($PFE), and olaparib is one of three promising oncology treatments the company believes can bring in $12 billion a year. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.